Department of Orthopedics and Traumatology, Mardin Training and Research Hospital, Mardin, Turkey.
Med Sci Monit. 2024 Aug 25;30:e945241. doi: 10.12659/MSM.945241.
BACKGROUND Reverse shoulder arthroplasty (RSA) is an accepted treatment that provides reproducible results in the treatment of rotator cuff deficiency and proximal humerus fractures. This single-center study aimed to evaluate the outcomes from reverse shoulder arthroplasty for rotator cuff ınsufficiency and proximal humerus fractures in 22 patients from a single center. MATERIAL AND METHODS Twenty-two patients were included in the study. The median age of the patients was 66 years (Range: 58-95). Proximal humerus fractures were diagnosed using X-ray and CT, while rotator cuff tears were diagnosed using MRI. For the assessment of joint function, the Constant-Murley score, the American Shoulder and Elbow Surgeons (ASES), and the Disabilities of Arm, Shoulder, and Hand (DASH) scores were used as patient-reported outcome measures. Kaplan-Meier analysis was conducted to evaluate implant survival. RESULTS The mean follow-up duration was 4.05±1.2 years. Significant improvements were observed: ASES Score: Increased from 35.8±2.8 to 81.3±5.4 (p<0.001). VAS Pain Score: Decreased from 7.3±1 to 2.9±0.9 (p<0.001). DASH Score: Improved from 66.3±4.3 to 32.5±3.6 (p<0.001). Constant-Murley Score: Increased from 48.3±3.5 to 74.6±7.7 (p<0.001). Kaplan-Meier analysis estimated implant survival at 6.7 years (95% CI, 6.3-7.2). CONCLUSIONS When performed with appropriate indications, RSA yields positive results, as seen in the literature and our study. Interscalene block anesthesia, advancements in implant technology, and adherence to surgical procedures can reduce RSA complications and ensure its safe application.
反式肩关节置换术(RSA)是一种被广泛接受的治疗方法,可在治疗肩袖缺损和肱骨近端骨折方面提供可重复的结果。本单中心研究旨在评估 22 例来自单一中心的肩袖缺损和肱骨近端骨折患者行反式肩关节置换术的结果。
本研究纳入 22 例患者。患者的中位年龄为 66 岁(范围:58-95 岁)。肱骨近端骨折通过 X 线和 CT 诊断,肩袖撕裂通过 MRI 诊断。为了评估关节功能,采用 Constant-Murley 评分、美国肩肘外科医师协会(ASES)评分和上肢残疾评分(DASH)作为患者报告的结果测量指标。采用 Kaplan-Meier 分析评估假体的存活率。
平均随访时间为 4.05±1.2 年。观察到以下显著改善:ASES 评分:从 35.8±2.8 增加到 81.3±5.4(p<0.001)。VAS 疼痛评分:从 7.3±1 降低至 2.9±0.9(p<0.001)。DASH 评分:从 66.3±4.3 改善至 32.5±3.6(p<0.001)。Constant-Murley 评分:从 48.3±3.5 增加至 74.6±7.7(p<0.001)。Kaplan-Meier 分析估计假体的 6.7 年存活率(95%CI,6.3-7.2)。
当适应症适当时,RSA 会产生如文献和我们的研究所示的积极结果。使用肌间沟阻滞麻醉、植入物技术的进步以及遵循手术程序可以减少 RSA 并发症并确保其安全应用。